查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995340

疫苗管瓶市场：按类型、材质、容量和瓶颈形式划分－2026-2032年全球市场预测

Vaccine Vials Market by Type, Material, Capacity, Neck Finish - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，疫苗管瓶市场价值将达到 7.7579 亿美元，到 2026 年将成长至 8.6527 亿美元，到 2032 年将达到 17.2683 亿美元，年复合成长率为 12.10%。

主要市场统计数据
基准年 2025 7.7579亿美元
预计年份：2026年 8.6527亿美元
预测年份：2032年 1,726,830,000 美元
复合年增长率 (%) 12.10%

疫苗管瓶市场正经历快速变革时期，其驱动力包括技术创新、不断变化的监管要求以及地缘政治因素对医疗供应链日益增长的影响。这些因素正在重塑製造商、合约填充商、供应商和卫生监管机构评估材料选择、生产基地选址和风险缓解策略的方式。如今，相关人员必须将传统做法与聚合物设计、玻璃配方和无菌填充技术的快速发展相协调，同时也要应对多规格产品线营运的复杂性。

本导言探讨了变革的关键驱动因素，包括材料替代性、需求波动下的生产力计画，以及贸易政策作为采购决策策略因素的日益重要。此外，本导言也重点介绍了扩大无菌生产规模所面临的实际挑战，例如验证计画、品管系统以及高等级生物安全灌装线的资本密集度。后续章节将这些趋势总结为实用见解，为必须在短期营运连续性和长期策略韧性之间取得平衡的决策者提供简洁扼要的指南。

在技​​术创新和政策转变的驱动下，变革性的变化正在重建疫苗管瓶生产、法律规范和供应链的韧性。

产业相关人员正见证着一场变革性的转变，这场转变超越了简单的製程改进，涵盖了管瓶设计、采购和监管的根本性变革。聚合物化学和阻隔性塑胶技术的进步提高了某些注射药物非玻璃包装方案的可行性，促使人们重新评估传统上占据主导地位的I型、II型和III型玻璃管瓶在某些应用情境下的优势。同时，自动化无菌填充和整合检测系统减少了生产线上的人工接触，缩短了品质放行前置作业时间，并降低了污染风险。反过来，这也影响包装材料的选择和生产线布局。

2025 年美国提案关税对管瓶製造成本、筹资策略和跨境供应链设计的累积影响分析。

预计2025年实施的关税措施将对管瓶生态系统内的采购经济和策略规划施加多方面的限制。这些措施不仅会影响到货成本，还会影响供应商认证的速度以及有关本地生产的投资决策。如果关税增加初级进口包装的成本，决策者将面临权衡：是自行承担增加的采购成本，还是将其转嫁给客户，抑或是加快用于建立和扩大国内生产能力的资本投资。

关键细分洞察揭示了管瓶类型、材料成分、容量范围和瓶颈端面选择如何影响製造复杂性和采用趋势。

市场细分为对整个管瓶市场的可操作性观点，突显了产品的复杂性、监管监管以及生产风险的集中程度。依产品类型划分，市场分为「多剂量」和「单剂量」製剂。这种区分对于填充和封盖策略、防腐剂的相容性以及包装线的更换频率至关重要。多剂量製剂引发了人们对防腐剂在反覆开启过程中的有效性和完整性的担忧，而单剂量製剂则优先考虑最大限度地减少萃取物和减少过量灌装，以确保剂量准确性。依材料划分，市场分为塑胶、I型玻璃、II型玻璃和III型玻璃。塑胶进一步细分为环烯烃聚合物和聚对苯二甲酸乙二醇酯，突显了它们在阻隔性能、生技药品和灭菌耐受性方面的差异。环烯烃聚合物具有低萃取物和优异的尺寸稳定性，使其适用于高度敏感的生技药品。另一方面，聚对苯二甲酸乙二醇酯在某些疫苗配方中具有成本和生产效率的优势。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和战略定位：重点关注需求驱动因素和製造地

每个地区都有其独特的管理体制、製造生态系统和物流实际情况，因此区域趋势会影响製造商、供应商和买家的策略选择。美洲拥有主要的需求中心和高度无菌的填充能力，通常辅以严格的法律规范和众多支持快速规模化的契约製造组织 (CMO)。该地区的采购决策受到支付方趋势和公共卫生疫苗接种策略的影响，这些因素决定了是优先考虑单剂疫苗的便利性还是多剂疫苗的经济性。

竞争格局分析，重点在于主要管瓶生产商的能力、产业重组趋势、创新投资和伙伴关係模式。

管瓶产业的企业策略主要围绕着几个核心优先事项：确保品质和符合法规要求、扩大产能，以及透过材料创新和服务整合实现差异化。主要企业正在投资自动化、线上检测和数位化品管系统，以缩短批次放行时间，并提高复杂价值链的可追溯性。其他企业则致力于垂直整合，进军玻璃加工和聚合物复合领域，以控制利润率并加速新型容器材料的认证。

为行业领导者提供实用建议，以优化韧性、投资灵活製造，并使商业化适应监管和贸易现实。

行业领导者应采取多管齐下的行动计划，在应对迫在眉睫的风险的同时，建立长期的组织韧性。首先，加快供应商认证通讯协定，将替代材料和区域供应商纳入其中，并将预测关税和物流中断的情境测试纳入采购决策模型。其次，投资建造灵活的模组化无尘室设施和自动化设备，以实现快速的产品形态变化，并减少对劳力密集作业的依赖。第三，加强材料表征程序，并记录从原料到成品管瓶的可追溯性，以满足日益严格的萃取物、浸出液和容器/密封系统完整性监管要求。

透明的调查方法，解释了所使用的资料来源、专家访谈、供应链映射和检验方法，以确保分析的严谨性。

本摘要采用定性和定量相结合的分析方法，以确保其稳健性和有效性。主要研究包括对製造业企业高阶主管、采购经理和监管专家进行结构化访谈，以了解实际营运和短期优先事项。除访谈外，还对材料安全文件、监管指南以及与无菌生产和容器/密封件测试相关的公开文件进行了技术审查。供应链图谱追踪了关键原料的流动，并识别出增加系统性风险的集中点。

此概要涉及整合法规、材料、生产能力和区域因素，以建构一个策略叙事，指南相关人员做出短期决策。

最终的综合分析结合了材料科学、製造经济学、监管预期和区域趋势，建构了一个连贯的叙事框架，为可操作的决策提供指导。材料选择仍然是决定产品性能和监管负担的核心因素，玻璃和先进聚合物之间的权衡会影响生物製药相容性、灭菌管道和永续性指标。透过投资自动化和模组化无尘室来提升製造柔软性，将决定企业能否快速应对需求激增和政策衝击。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：疫苗管瓶市场：依类型划分

  • 多次给药
  • 单一剂量

第九章：疫苗管瓶市场：依材料分类

  • 塑胶
    • 环烯烃聚合物
    • 聚对苯二甲酸乙二酯
  • I型玻璃
  • II 型玻璃
  • 第三型玻璃

第十章：疫苗管瓶市场：依产能划分

  • 10ml
  • 2ml
  • 20ml
  • 5ml

第十一章：疫苗管瓶市场：以瓶颈端型划分

  • 卷边
  • 拧紧

第十二章：疫苗管瓶市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：疫苗管瓶市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：疫苗管瓶市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国疫苗管瓶市场

第十六章：中国疫苗管瓶市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Ardagh Group SA
  • Bormioli Pharma SpA
  • Corning Incorporated
  • Gerresheimer AG
  • Nipro Corporation
  • SCHOTT AG
  • SGD Pharma SA
  • Shandong Pharmaceutical Glass Co., Ltd.
  • Stevanato Group SpA
  • Vitro, SAB de CV
Product Code: MRR-F74E250AD5FF

The Vaccine Vials Market was valued at USD 775.79 million in 2025 and is projected to grow to USD 865.27 million in 2026, with a CAGR of 12.10%, reaching USD 1,726.83 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 775.79 million
Estimated Year [2026] USD 865.27 million
Forecast Year [2032] USD 1,726.83 million
CAGR (%) 12.10%

The vaccine vial landscape has entered a period of accelerated transformation driven by technological innovation, evolving regulatory requirements, and heightened geopolitical attention to medical supply chains. These forces are reshaping how manufacturers, contract packagers, suppliers, and health authorities assess material choices, production footprints, and risk mitigation strategies. Stakeholders must now reconcile legacy practices with rapid advances in polymer design, glass formulation, and aseptic filling technologies while managing the operational complexity of multi-format product lines.

This introduction frames the key vectors of change: material substitution possibilities, capacity planning under variable demand profiles, and the emergence of trade policy as a strategic factor in sourcing decisions. It also underscores the practical realities of scaling sterile manufacturing, such as validation timelines, quality management systems, and the capital intensity of high-containment filling lines. The following sections synthesize these dynamics into actionable insights, offering a concise orientation for decision-makers who must balance short-term operational continuity with longer-term strategic resilience.

Transformative shifts reshaping vaccine vial production, regulatory oversight, and supply chain resilience driven by technological innovation and policy changes

Industry participants are witnessing transformative shifts that extend beyond incremental process improvements to fundamental changes in how vials are designed, sourced, and regulated. Advances in polymer chemistry and high-barrier plastic technologies have elevated the viability of non-glass solutions for certain injectables, prompting reconsideration of traditional Type I, II, and III glass dominance in some use cases. Simultaneously, automated aseptic filling and integrated inspection systems are reducing human touchpoints on the line, shortening turnaround for quality release and lowering contamination risk, which in turn affects packaging selection and line layout.

Regulatory authorities are reinforcing focus on extractables and leachables, container closure integrity, and supply chain transparency, requiring manufacturers to provide deeper material characterization and provenance data. Trade policy and national security considerations have introduced new imperatives for regional supply capability, motivating investments in nearshore manufacturing and dual-sourcing strategies. These shifts are producing higher expectations for vendor traceability, accelerated qualification of alternative materials, and expanded collaboration between material suppliers and filling partners to co-develop validated solutions that meet both regulatory and operational criteria. In sum, the landscape is transitioning from a transactional buyer-supplier model to a collaborative, risk-managed ecosystem where cross-functional alignment is essential.

Cumulative impact analysis of proposed United States tariffs in 2025 on vial manufacturing costs, sourcing strategies, and cross-border supply chain design

Anticipated tariff actions in 2025 introduce a multi-dimensional constraint on sourcing economics and strategic planning for the vial ecosystem. Tariff measures affect not only landed cost but also the cadence of supplier qualification and the calculus of localized manufacturing investments. Where tariffs raise the cost of imported primary packaging, decision-makers face trade-offs between absorbing higher procurement costs, passing them through to customers, or accelerating capital deployment to establish or expand domestic production capacity.

The cumulative impact manifests across procurement cycle times, inventory policies, and supplier relationships. Organizations with lean inventory posture will feel near-term pressure to re-evaluate safety stock levels and to negotiate longer-term commitments with qualified suppliers to secure continuity. Conversely, firms with flexible manufacturing platforms and modular cleanroom designs can pivot more rapidly to alternate materials or localized suppliers, thereby mitigating tariff exposure. Strategic procurement teams will increasingly layer scenario planning into supplier scorecards, applying sensitivity analysis to tariff scenarios to guide capacity investments and contract terms. Ultimately, tariff-driven dynamics reinforce the value of diversified sourcing, investment in supplier development, and early engagement with regulators to ensure that any material or manufacturer changes remain compliant and auditable.

Key segmentation insights revealing how vial type, material composition, capacity ranges, and neck finish choices drive manufacturing complexity and adoption trends

Segmentation offers a practical lens to understand where product complexity, regulatory scrutiny, and manufacturing risk concentrate across the vial landscape. Based on Type, market is studied across Multi Dose and Single Dose, a distinction that matters for fill-finish strategy, preservative compatibility, and packaging line changeover frequency. Multi-dose formats drive concerns around preservative efficacy and repeated access integrity, while single-dose formats prioritize minimal extractables and lower overfill to support dosing accuracy. Based on Material, market is studied across Plastic, Type I Glass, Type II Glass, and Type III Glass. The Plastic is further studied across Cyclo Olefin Polymer and Polyethylene Terephthalate, a subdivision that highlights differences in barrier performance, compatibility with biologics, and sterilization resilience. Cyclo olefin polymers bring low extractables and excellent dimensional stability, making them attractive for sensitive biologics, whereas polyethylene terephthalate offers cost and throughput advantages for certain vaccine formulations.

Based on Capacity, market is studied across 10 Ml, 2 Ml, 20 Ml, and 5 Ml, a range that reflects clinical and programmatic dosing strategies and influences vial dimensions, neck finish requirements, and handling ergonomics on high-speed lines. Smaller capacities increase format proliferation and demand tighter tolerance control, whereas larger volumes reduce unit handling but require robust overfill controls and container closure integrity testing. Based on Neck Finish, market is studied across Crimp and Screw, which determines closure systems, sealing equipment, and compatibility with automated capping or crimping stations. Crimp finishes dominate traditional sterile parenteral supply chains because of proven hermetic seals with aluminum caps and rubber stoppers, while screw finishes enable faster assembly in some low-sterility settings and different sealing paradigms. Together, these segmentation vectors create a matrix of product and process decisions that influence design for manufacturability, regulatory submission content, and supplier selection criteria.

Regional dynamics and strategic positioning across Americas, Europe Middle East and Africa, and Asia-Pacific highlighting demand drivers and manufacturing hubs

Regional dynamics shape strategic choices for manufacturers, suppliers, and purchasers because each geography combines distinct regulatory regimes, manufacturing ecosystems, and logistics realities. Americas hosts significant demand centers and advanced aseptic filling capacity, often paired with stringent regulatory oversight and a large base of contract manufacturing organizations that support rapid scale-up. Its procurement decisions are influenced by payer dynamics and public health vaccination strategies, which in turn affect preferences for single-dose convenience versus multi-dose economy.

Europe, Middle East & Africa presents a heterogeneous landscape in which regulatory harmonization across the European Union coexists with capacity constraints and distribution challenges in several countries. Manufacturers in this region contend with high expectations for material characterization and environmental compliance while also navigating complex cross-border logistics across multiple jurisdictions. Asia-Pacific combines both large-scale manufacturing hubs and rapidly expanding domestic demand centers, supported by lower-cost production capabilities and a growing base of material suppliers offering glass and polymer solutions. Investment patterns here frequently favor high-volume production and vertical integration to capture efficiencies. Across all regions, proximity to end markets, customs regimes, and trade policy interplay to determine whether companies prioritize nearshoring, regional distribution centers, or global sourcing models, with risk-averse organizations tending toward diversified regional footprints to minimize single-point failures.

Competitive landscape intelligence focusing on capabilities, consolidation trends, innovation investments, and partnership models among leading vial manufacturers

Company strategies in the vial sector coalesce around a few core priorities: securing quality and regulatory compliance, scaling productive capacity, and differentiating through material innovation or service integration. Leading manufacturers are investing in automation, inline inspection, and digital quality systems to reduce batch release times and to improve traceability across complex value chains. Others pursue vertical integration into glass processing or polymer compounding to control margins and to accelerate qualification of novel container materials.

Partnership models are increasingly important; collaborations between material suppliers, primary packaging manufacturers, and contract fillers enable co-development programs that shorten validation timelines and align packaging properties with specific biologic attributes. Consolidation activity, strategic alliances, and targeted M&A are shaping capability footprints, but many organizations still compete on service responsiveness and the depth of regulatory support they offer customers. As environmental sustainability becomes a procurement criterion, firms that can demonstrate lifecycle analysis and recycling pathways for both glass and plastic containers gain preferential consideration among institutional buyers and public health agencies. Ultimately, competitive advantage flows from the ability to deliver validated, regulatory-ready containers at the scale and speed demanded by vaccination programs while maintaining cost discipline and supply assurance.

Actionable recommendations for industry leaders to optimize resilience, invest in flexible manufacturing, and align commercialization with regulatory and trade realities

Industry leaders should adopt a multi-pronged action plan that addresses immediate risks while positioning their organizations for longer-term resilience. First, accelerate supplier qualification protocols to include alternative materials and regional sources, and integrate scenario testing for tariff and logistics disruptions into procurement decision models. Second, invest in flexible, modular cleanroom capacity and automation that allow rapid format changeover and reduce dependence on labor-intensive operations. Third, strengthen material characterization programs to meet heightened regulatory expectations for extractables, leachables, and container closure integrity, documenting traceability from raw material to finished vial.

Leaders must also deepen collaborative ties with contract manufacturers, material suppliers, and regulatory consultants to co-create validated solutions and to shorten time-to-market for format changes. Build cross-functional war rooms that bring procurement, quality, regulatory, and operations together to evaluate trade-offs and to coordinate risk mitigation. Finally, embed environmental and circularity considerations into packaging strategies by assessing reuse and recycling pathways for both glass and plastic, and by communicating sustainability metrics to buyers and regulators. These steps will reduce vulnerability to trade shocks, improve responsiveness to shifting demand profiles, and create competitive differentiation based on reliability and regulatory readiness.

Transparent research methodology describing data sources, expert interviews, supply chain mapping, and validation approaches used to ensure rigorous analysis

The analytical approach underpinning this summary combined qualitative and quantitative methods to ensure robustness and relevance. Primary research included structured interviews with manufacturing executives, procurement leaders, and regulatory experts to capture operational realities and near-term priorities. These interviews were complemented by technical reviews of material safety dossiers, regulatory guidance documents, and public filings related to aseptic manufacturing and container closure testing. Supply chain mapping exercises traced key raw material flows and identified concentration points that elevate systemic risk.

Secondary analysis leveraged industry-standard technical literature on glass formulations, polymer science, and aseptic filling best practices to validate observed trends. Findings were triangulated across sources to reduce bias and to ensure conclusions reflected convergent evidence rather than isolated perspectives. Peer review by domain experts and subject-matter validation against publicly available regulatory outcomes further strengthened the methodology. The research process emphasized transparency, reproducibility, and operational relevance, producing insights that are grounded in practitioner experience and supported by technical documentation.

Concluding synthesis that integrates regulatory, material, capacity, and regional factors into a strategic narrative for stakeholders to inform near-term decisions

The concluding synthesis integrates material science, manufacturing economics, regulatory expectations, and regional dynamics into a cohesive narrative that guides practical decision-making. Material selection remains a central determinant of product performance and regulatory burden, with trade-offs between glass and advanced polymers affecting compatibility with biologics, sterilization pathways, and sustainability metrics. Manufacturing flexibility, enabled by automation and modular cleanroom investments, will determine which organizations can respond quickly to both demand surges and policy shocks.

Regulatory scrutiny and trade policy are now strategic variables that shape sourcing and capacity decisions; organizations that proactively qualify alternatives, document material provenance, and cultivate regional supplier networks will reduce exposure to disruption. Finally, collaboration across the ecosystem-bringing together material scientists, contract fillers, procurement professionals, and regulators-will be essential to deliver validated, scalable solutions. This synthesis points to a practical horizon in which resilience, technical rigor, and strategic partnerships together form the basis for competitive advantage in the vaccine vial sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaccine Vials Market, by Type

  • 8.1. Multi Dose
  • 8.2. Single Dose

9. Vaccine Vials Market, by Material

  • 9.1. Plastic
    • 9.1.1. Cyclo Olefin Polymer
    • 9.1.2. Polyethylene Terephthalate
  • 9.2. Type I Glass
  • 9.3. Type II Glass
  • 9.4. Type III Glass

10. Vaccine Vials Market, by Capacity

  • 10.1. 10 Ml
  • 10.2. 2 Ml
  • 10.3. 20 Ml
  • 10.4. 5 Ml

11. Vaccine Vials Market, by Neck Finish

  • 11.1. Crimp
  • 11.2. Screw

12. Vaccine Vials Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Vaccine Vials Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Vaccine Vials Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Vaccine Vials Market

16. China Vaccine Vials Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Ardagh Group S.A.
  • 17.6. Bormioli Pharma S.p.A.
  • 17.7. Corning Incorporated
  • 17.8. Gerresheimer AG
  • 17.9. Nipro Corporation
  • 17.10. SCHOTT AG
  • 17.11. SGD Pharma S.A.
  • 17.12. Shandong Pharmaceutical Glass Co., Ltd.
  • 17.13. Stevanato Group S.p.A.
  • 17.14. Vitro, S.A.B. de C.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VACCINE VIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VACCINE VIALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VACCINE VIALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINE VIALS MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE VIALS MARKET SIZE, BY CAPACITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINE VIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VACCINE VIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE VIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES VACCINE VIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA VACCINE VIALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VACCINE VIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VACCINE VIALS MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE VIALS MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE VIALS MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VACCINE VIALS MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VACCINE VIALS MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE VIALS MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE VIALS MARKET SIZE, BY PLASTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE VIALS MARKET SIZE, BY PLASTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE VIALS MARKET SIZE, BY PLASTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE VIALS MARKET SIZE, BY CYCLO OLEFIN POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE VIALS MARKET SIZE, BY CYCLO OLEFIN POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE VIALS MARKET SIZE, BY CYCLO OLEFIN POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE VIALS MARKET SIZE, BY POLYETHYLENE TEREPHTHALATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE VIALS MARKET SIZE, BY POLYETHYLENE TEREPHTHALATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE VIALS MARKET SIZE, BY POLYETHYLENE TEREPHTHALATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE I GLASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE I GLASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE I GLASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE II GLASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE II GLASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE II GLASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE III GLASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE III GLASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE III GLASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VACCINE VIALS MARKET SIZE, BY 10 ML, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VACCINE VIALS MARKET SIZE, BY 10 ML, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VACCINE VIALS MARKET SIZE, BY 10 ML, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE VIALS MARKET SIZE, BY 2 ML, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE VIALS MARKET SIZE, BY 2 ML, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE VIALS MARKET SIZE, BY 2 ML, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE VIALS MARKET SIZE, BY 20 ML, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINE VIALS MARKET SIZE, BY 20 ML, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VACCINE VIALS MARKET SIZE, BY 20 ML, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VACCINE VIALS MARKET SIZE, BY 5 ML, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE VIALS MARKET SIZE, BY 5 ML, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VACCINE VIALS MARKET SIZE, BY 5 ML, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VACCINE VIALS MARKET SIZE, BY CRIMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VACCINE VIALS MARKET SIZE, BY CRIMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VACCINE VIALS MARKET SIZE, BY CRIMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VACCINE VIALS MARKET SIZE, BY SCREW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VACCINE VIALS MARKET SIZE, BY SCREW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VACCINE VIALS MARKET SIZE, BY SCREW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VACCINE VIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS VACCINE VIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA VACCINE VIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VACCINE VIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 105. GCC VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 108. GCC VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 109. GCC VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 110. GCC VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 123. G7 VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 126. G7 VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 127. G7 VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 128. G7 VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 129. NATO VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 132. NATO VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 133. NATO VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 134. NATO VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES VACCINE VIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA VACCINE VIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)